Jacono A, Caso P, Gualtieri S, Raucci D, Bianchi A, Vigorito C, Bergamini N, Iadevaia V
Eur J Rheumatol Inflamm. 1981;4(1):32-5.
Possible interactions between indoprofen (IP) and Warfarin Na (W) were studied in 18 patients under chronic anticoagulant treatment, according to a cross-over, double-blind design, comparing 600 mg daily of IP with placebo (PL). In all subjects the dosage of W was kept constant throughout the study (21 days). No significant differences were found between IP and PL either on coagulation parameters or on platelet count and platelet adhesiveness. Afte IP a significant decrease in platelet aggregation (induced by ADP and adrenaline) was observed. The results suggest that indoprofen can be administered to patients under anticoagulant treatment, although frequent checks of the coagulation parameters are advisable in these cases.
根据交叉、双盲设计，对18例接受慢性抗凝治疗的患者进行了研究，比较每日600毫克消炎痛（IP）与安慰剂（PL）之间的相互作用。在所有受试者中，整个研究（21天）期间华法林钠（W）的剂量保持恒定。在凝血参数、血小板计数和血小板黏附性方面，IP组和PL组之间未发现显著差异。服用IP后，观察到血小板聚集（由ADP和肾上腺素诱导）显著降低。结果表明，消炎痛可用于接受抗凝治疗的患者，尽管在这些情况下建议经常检查凝血参数。
